 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12...1213141516171819202122...229230» |
- | cisplatin / Generic mfg., nicorandil / Generic mfg.
Preclinical, Journal, IO biomarker: Nicorandil attenuates cisplatin-induced acute kidney injury in rats via activation of PI3K/AKT/mTOR signaling cascade and inhibition of autophagy. (Pubmed Central) - Jan 18, 2024
Our study showed the nephroprotective effects of nicorandil in cisplatin-induced AKI in rats via activation of PI3K/AKT/mTOR signaling cascade, inhibition of autophagy, anti-inflammatory, anti-apoptotic, anti-oxidant activities. Thus, nicorandil could represent a promising renoprotective agent in cancer patients treated with cisplatin.
- | Preclinical, Journal: Liensinine alleviates mouse intestinal injury induced by sepsis through inhibition of oxidative stress, inflammation, and cell apoptosis. (Pubmed Central) - Jan 18, 2024
And then it reduced the excessive apoptosis of intestinal cells. This study provides valuable insights for sepsis prevention and treatment, offering a potential therapeutic candidate to protect against intestinal injury and regulate the inflammatory response in sepsis.
- | Journal, IO biomarker: MiR-29a mediates the apoptotic effects of TNF-? on endothelial cells through inhibiting PI3K/AKT/BCL-2 axis. (Pubmed Central) - Jan 18, 2024
Mediating the inflammation-driven endothelial cell apoptosis is an important biology mechanism by which miR-29a promotes atherosclerosis and its complications. MiR-29a will be a potential diagnostic and therapeutic target for atherosclerotic cardiovascular diseases; it is worthwhile to further study.
- Piqray (alpelisib) / Novartis, defactinib (VS-6063) / Verastem
The Role And Mechanism Of KMT2D To Modulate PI3Ka Inhibitor Response In Cervical Cancer Identified By CRISPR/Cas9 Genome-Wide Screening (Poster area) - Jan 18, 2024 - Abstract #ESGO2024ESGO_797;
This study provides insights for clinical trials, emphasizing the potential of KMT2D as a predictive marker for PI3K? inhibitors in cervical cancer treatment.
- Piqray (alpelisib) / Novartis
Alpelisib For PIK3CA-Mutated Advanced Gynecological Cancers: First Clues Of Clinical Activity (Poster area) - Jan 18, 2024 - Abstract #ESGO2024ESGO_352;
Conclusion Alpelisib represents an active treatment option in patients with recurrent gynecological cancers harboring a PIK3CA mutation. These findings support the need of biomarker-driven randomized trials of PI3K inhibitors in gynecological cancers.
- Aliqopa (copanlisib) / Bayer
Trial completion date, Trial primary completion date, Combination therapy: Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations (clinicaltrials.gov) - Jan 17, 2024
P2, N=7, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
These findings support the need of biomarker-driven randomized trials of PI3K inhibitors in gynecological cancers. Trial completion date: Oct 2026 --> Aug 2024 | Trial primary completion date: Oct 2026 --> Aug 2024
- | LY294002 / Eli Lilly, PD98059 / Wayne State University
Journal: NCAM mimetic peptide P2 synergizes with bone marrow mesenchymal stem cells in promoting functional recovery after stroke. (Pubmed Central) - Jan 17, 2024
Treatment with LY294002 (PI3K inhibitor) and PD98059 (ERK inhibitor) decreased the neuroprotective effects of combined P2 and BMSC therapy in MCAO rats. Collectively, P2 is neuroprotective while P2 and BMSCs work synergistically to improve functional outcomes after ischemic stroke, which may be attributed to mechanisms involving enhanced BMSC proliferation and neurotrophic factor release, anti-apoptosis, and PI3K/AKT and ERK pathways activation.
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Journal: Suppression of malignant melanoma by knocking down growth differentiation factor-15 via inhibiting PTEN/PI3K/AKT signaling pathway. (Pubmed Central) - Jan 17, 2024
GDF15 regulated the cell proliferation, apoptosis, migration, invasion, and EMT process of M14 and M21 cell lines through targeting PTEN/PI3K/AKT signaling pathway. This research provides a novel prevention and treatment strategy for melanoma.
- || Review, Journal: Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects. (Pubmed Central) - Jan 17, 2024
This article provides a comprehensive review of the structure and biological functions, and clinical status of PI3K inhibitors, with a specific emphasis on the development strategies and structure-activity relationships of dual-target PI3K inhibitors. The findings offer valuable insights and future directions for the development of highly promising dual-target drugs targeting PI3K.
- | Calsed (amrubicin) / Sumitomo Pharma, BMS
Journal: Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma. (Pubmed Central) - Jan 17, 2024
These findings indicate that AMR-PLGA-NPs can be an effective and flexible nanoplatform for treating GBM while addressing drug resistance issues. Overall, the study demonstrates the potential of AMR-PLGA-NPs as a stable and safe treatment option for GBM, addressing the major issue of drug resistance in these types of tumors. .
- | LY294002 / Eli Lilly
Journal: Modified Guo-Min decoction ameliorates PM2.5-induced lung injury by inhibition of PI3K-AKT and MAPK signaling pathways. (Pubmed Central) - Jan 17, 2024
The results of this study support and provide scientific evidence for the clinical application of MGMD on PM2.5-induced lung injury. Pre-treatment, sync-treatment, and post-treatment is the highlight of this study.
- | LY294002 / Eli Lilly
Journal: MiR-150-5p contributes to unexplained recurrent spontaneous abortion by targeting VEGFA and downregulating the PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Jan 17, 2024
Pre-treatment, sync-treatment, and post-treatment is the highlight of this study. Overall, these findings imply that miR-150-5p is among the key factors that regulate the pathogenesis of URSA.
- | Journal: Low-dose Lipopolysaccharide Alleviates Spinal Cord Injury-induced Neuronal Inflammation by Inhibiting microRNA-429-mediated Suppression of PI3K/AKT/Nrf2 Signaling. (Pubmed Central) - Jan 17, 2024
Inhibition of miR-429 blocked low-dose LPS-mediated oxidative stress and inflammation via activation of the PI3K/AKT/Nrf2 pathway. Overall, low-dose LPS was found to alleviate SCI-induced neuronal oxidative stress and inflammatory response by down-regulating miR-429 to activate the PI3K/AKT/Nrf2 pathway.
- | fenofibrate / Generic mfg.
Journal: Fenofibrate suppresses the progression of hepatoma by downregulating osteopontin through inhibiting the PI3K/AKT/Twist pathway. (Pubmed Central) - Jan 17, 2024
Furthermore, the inhibitory effect of fenofibrate on the PI3K/AKT/Twist pathway in Hep3B cells and Hep3B xenograft model was abrogated by OPN overexpression. Collectively, fenofibrate suppressed progression of hepatoma downregulating OPN through inhibiting the PI3K/AKT/Twist pathway.
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
Journal: HDAC inhibitors target IRS4 to enhance anti?AR therapy in AR?positive triple?negative breast cancer. (Pubmed Central) - Jan 16, 2024
In conclusion, the results of the present study revealed that combination treatment with Enz and Chid can upregulate IRS4, which results in the blocking of KRAS signalling and suppression of tumour growth. It may be hypothesised that the expression levels of IRS4 could be used as a biomarker for screening patients with AR?positive TNBC using Enz and Chid combination therapy.
- | Journal: Chemical Proteomics and Morphological Profiling Revealing MYDGF as a Target for Synthetic Anticancer Macromolecules. (Pubmed Central) - Jan 16, 2024
Through morphological profiling, we also identify similarities in phenotypic effects of the functionalized polycarbonates with topoisomerase I inhibitors, MDM2 inhibitors, and phosphatidylinositol 3kinase inhibitors against cancer cells, suggesting a common mechanism through the PIK3/AKT pathway leading to apoptosis. These findings present the first macromolecular compound targeting MYDGF and may serve as an example for MYDGF modulation as a potential new target for macromolecular chemotherapeutic development.
- | LY294002 / Eli Lilly
Preclinical, Journal, IO biomarker: Chuanzhitongluo inhibits neuronal apoptosis in mice with acute ischemic stroke by regulating the PI3K/AKT signaling pathway. (Pubmed Central) - Jan 16, 2024
These findings present the first macromolecular compound targeting MYDGF and may serve as an example for MYDGF modulation as a potential new target for macromolecular chemotherapeutic development. These findings imply that CZTL's ability to inhibit neuronal apoptosis may be linked to the activation of AIS's PI3K/AKT signaling pathway.
- | Journal: Study on the mechanism of action of Saposhnikovia divaricata and its key phytochemical on rheumatoid arthritis based on network pharmacology and bioinformatics. (Pubmed Central) - Jan 15, 2024
Our findings provide insights into the therapeutic effects of SD on RA, successfully predicting the effective ingredients and potential targets, which could suggest a novel theoretical basis for further exploration of its molecular mechanisms. It also revealed that Prangenidin inhibited viability, migration, invasion, cytokine, and MMPs expression, and induced apoptosis in RA FLSs via the PI3K/AKT pathway.
- | Journal: Enhanced VEGF secretion and blood-brain barrier disruption: Radiation-mediated inhibition of astrocyte autophagy via PI3K-AKT pathway activation. (Pubmed Central) - Jan 15, 2024
In conclusion, our study suggests that radiation can inhibit autophagy and promote VEGF oversecretion by upregulating the PI3K-AKT pathway in astrocytes. Blocking the PI3K pathway can alleviate both of these effects, thereby mitigating damage to the BBB in patients undergoing radiation treatment.
- | Journal: Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids. (Pubmed Central) - Jan 15, 2024
The combination of MAPK and PI3K inhibitors reversed Braf oncogene-promoted cell dedifferentiation while restoring thyroid follicle organization and function in vitro. Our results demonstrate that pluripotent stem cells-derived thyroid cancer organoids can mimic tumor development and features while providing an efficient tool for testing novel targeted therapies.
- | Venclexta (venetoclax) / Roche, AbbVie, Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
Journal: Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia. (Pubmed Central) - Jan 15, 2024
P1/2
Time-limited venetoclax and U2 is safe and highly effective combination therapy for relapsed/refractory CLL patient including those who have been previously treated with covalent BTK inhibitors. This trial was registered on ClinicalTrials.gov under identifier: NCT03379051.
- | Victoza (liraglutide) / Novo Nordisk
Journal: Liraglutide attenuates obese-associated breast cancer cell proliferation via inhibiting PI3K/Akt/mTOR signaling pathway. (Pubmed Central) - Jan 15, 2024
Our results reveal that transfection of AMPK/SIRT-1 genes did not affect the beneficial role of LGT in the expression of adipokines in ADSCs. In conclusion, LGT elicits anti-proliferative, apoptotic, and anti-migratory effects on BC cells in obese conditions by suppressing the activity of survival pathways; however, this effect is independent of the AMPK/SIRT1 pathway in ADSCs or AMPK in BC cells.
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Journal: Essential Oil of Matricaria chamomilla Alleviate Psoriatic-Like Skin Inflammation by Inhibiting PI3K/Akt/mTOR and p38MAPK Signaling Pathway. (Pubmed Central) - Jan 15, 2024
At the same time, we prepared imiquimod-induced psoriatic-like skin inflammation in mice to investigate thoroughly the potential inhibition functions of MCEO on psoriatic skin injury and inflammation...MCEO ameliorated skin injury in IMQ-induced psoriatic-like skin inflammation of mice by downregulating the levels of inflammatory cytokines but not IL-17A. Thus, anti-inflammatory plant drugs with different targets with combined applications were a potential therapeutic strategy in psoriasis.
- | Journal: Nanoemulsion potentiates the anti-cancer activity of Myricetin by effective inhibition of PI3K/AKT/mTOR pathway in triple-negative breast cancer cells. (Pubmed Central) - Jan 14, 2024
Mechanistic investigation revealed that nanoemulsion augmented the anti-cancer efficacy of Myricetin, most likely by inhibiting the PI3K/AKT/mTOR pathway, eventually leading to enhanced cell death in TNBC cells. The study provides substantial experimental evidence to support the notion that the Myr-NE formulation has the potential to be an effective therapeutic drug for TNBC treatment.
- | Preclinical, Journal: Exploration of anti?osteosarcoma activity of asiatic acid based on network pharmacology and in (Pubmed Central) - Jan 12, 2024
In addition, asiatic acid decreased the levels of phosphorylated (p?)PI3K/PI3K and p?AKT/AKT, increased reactive oxygen species (ROS) and upregulated the levels of p?ERK1/2/ERK1/2, p?p38/p38 and p?JNK/JNK in osteosarcoma cells. These results demonstrated that asiatic acid inhibited osteosarcoma cells proliferation by inhibiting PI3K/AKT and activating ROS/MAPK signaling pathways, suggesting asiatic acid is a potential agent against osteosarcoma.
- | imatinib / Generic mfg.
Journal, PARP Biomarker, IO biomarker: Imatinib inhibits oral squamous cell carcinoma by suppressing the PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Jan 12, 2024
Furthermore, imatinib suppressed migration and colony formation while promoting OSCC cell apoptosis by enhancing p53, Bax, and PARP expression levels and reducing Bcl-2 expression. Imatinib also inhibited the PI3K/AKT/mTOR signaling pathway and induced OSCC cell apoptosis, demonstrating the potential of imatinib as a treatment for oral cancer.
- | elimusertib (BAY 1895344) / Bayer, Aliqopa (copanlisib) / Bayer
Journal: The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib. (Pubmed Central) - Jan 11, 2024
This activity is present in both DDR-proficient and DDR-deficient lymphoma models. Furthermore, a combination of ATR and PI3K inhibition by treatment with elimusertib and copanlisib has in
- || palazestrant (OP-1250) / Olema Pharma
Phase classification, Enrollment change, Combination therapy, Metastases: Phase 1b Combo w/ Ribociclib and Alpelisib (clinicaltrials.gov) - Jan 11, 2024
P1, N=90, Recruiting, Sponsor: Olema Pharmaceuticals, Inc.
Furthermore, a combination of ATR and PI3K inhibition by treatment with elimusertib and copanlisib has in Phase classification: P1b --> P1 | N=60 --> 90
- | Journal: A combined opposite targeting of p110? PI3K and RhoA abrogates skin cancer. (Pubmed Central) - Jan 10, 2024
Together, our findings highlight the importance of targeting cancer cells and macrophages for skin cancer therapy, emerge a reverse link between ATX and RhoA and illustrate the benefit of p110? PI3K inhibition as a combinatorial regimen for the treatment of skin cancers.
- || paxalisib (GDC-0084) / Kazia
PK/PD data, Preclinical, Journal: Preclinical Characterization of the Absorption and Disposition of the Brain Penetrant PI3K/mTOR Inhibitor Paxalisib and Prediction of Its Pharmacokinetics and Efficacy in Human. (Pubmed Central) - Jan 10, 2024
Oral bioavailability ranged from 6% in monkeys to 76% in rats.The parameters estimated from the pharmacokinetic/pharmacodynamic modeling of the efficacy in the subcutaneous U87 xenograft model combined with the human pharmacokinetics profile predicted by PBPK modeling suggested that a dose of 56?mg may be efficacious in humans. Paxalisib is currently tested in Phase III clinical trials.
- | PF-04979064 / Pfizer
Journal: Dual PI3K/mTOR inhibitor PF-04979064 regulates tumor growth in gastric cancer and enhances drug sensitivity of gastric cancer cells to 5-FU. (Pubmed Central) - Jan 10, 2024
Western blot results showed that PF-04979064 significantly inhibited the PI3K/AKT/mTOR signaling pathway in GC cells, whereas RNA seq results demonstrated substantial alterations in gene expression profiles upon treatment with PF-04979064. This study provides insight into the effects of PF-04979064, thereby establishing a solid foundation for its potential clinical application in the treatment of GC.
- | LY294002 / Eli Lilly
Journal: Rosmarinic acid alleviate CORT-induced depressive-like behavior by promoting neurogenesis and regulating BDNF/TrkB/PI3K signaling axis. (Pubmed Central) - Jan 10, 2024
More importantly, LY294002, but not ANA-12, reversed the effect of RA on GR nuclear translocation. Taken together, RA exerted antidepressant activities by modulating the hippocampal glucocorticoid signaling and hippocampal neurogenesis, which related to the BDNF/TrkB/PI3K signaling axis regulating GR nuclear translocation, provide evidence for the application of RA as a candidate for depression.
- | LY294002 / Eli Lilly
Preclinical, Journal: Periplaneta americana extract promotes hard palate mucosal wound healing via the PI3K/AKT signaling pathway in male mice. (Pubmed Central) - Jan 10, 2024
Taken together, RA exerted antidepressant activities by modulating the hippocampal glucocorticoid signaling and hippocampal neurogenesis, which related to the BDNF/TrkB/PI3K signaling axis regulating GR nuclear translocation, provide evidence for the application of RA as a candidate for depression. Periplaneta americana extract shows promising effects for the promotion of hard palate mucosal wound healing and may be a novel candidate for clinical translation.
- | Journal, PD(L)-1 Biomarker, IO biomarker: FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. (Pubmed Central) - Jan 10, 2024
These biological effects are achieved by inhibiting the PI3K/AKT pathway. The combination of FGFR4 knockdown and anti-PD-1 antibody greatly suppressed tumor growth and enhanced the sensitivity of immunotherapy, highlighting the clinical significance of FGF19/FGFR4 activation in immunotherapy.
- | dexamethasone / Generic mfg.
Journal: Synergistic combination of isogarcinol isolated from edible fruits of Garcinia multiflora and dexamethasone to overcome leukemia glucocorticoid resistance. (Pubmed Central) - Jan 10, 2024
Furthermore, western blot analysis revealed that ISO and DEX inhibits the PI3K/Akt/mTOR signaling pathway and promotes the nuclear translocation of glucocorticoid receptor (GR), which activates target genes NR3C1 and TSC22D3, leading to apoptosis in Jurkat cells. Hence, our results suggest that ISO, as a safe and effective food-derived agent, can enhance the anti-leukemia effects of DEX.
- | Journal: Integration of network pharmacology and serum medicinal chemistry to investigate the pharmacological mechanisms of QiZhuYangGan Decoction in the treatment of hepatic fibrosis. (Pubmed Central) - Jan 9, 2024
QZD may be effective in the treatment of hepatic fibrosis by inhibiting the PI3K/AKT/mTOR signaling pathway and M1 macrophage polarization, while promoting M2 macrophage polarization. This provides a strong basis for the clinical application of QZD.
- | BR101801 / Boryung Group
Journal: BR101801 enhances the radiosensitivity of p53-deficient colorectal cancer cells by inducing G2/M arrest, apoptosis, and senescence in a p53-independent manner. (Pubmed Central) - Jan 8, 2024
Moreover, BR101801 exerted robust synergistic effects on IR-induced cell cycle arrest, apoptosis, and tumor growth inhibition, even in radioresistant HCT116 p53 cells. Overall, these findings provide a scientific rationale for combining BR101801 with IR as a new therapeutic strategy to overcome radioresistance induced by p53 deficiency.
- | Journal: Conformationally regulated "nanozyme-like" cerium oxide with multiple free radical scavenging activities for osteoimmunology modulation and vascularized osseointegration. (Pubmed Central) - Jan 8, 2024
RNA sequencing and mechanism exploration suggested that the inhibition of PI3K-AKT signaling pathway was essential for immunomodulatory capacity of NF. In conclusion, it provided promising insights into the immunomodulatory exploitation of orthopedic implants.
- || Review, Journal: Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway. (Pubmed Central) - Jan 8, 2024
Overcoming resistance to PI3K inhibitors and exploring combination therapies are addressed as important considerations. While this field holds promise in improving patient outcomes, further research and clinical trials are needed to validate these approaches and translate them into clinical practice.
- || Review, Journal: Development of small-molecule inhibitors that target PI3K?. (Pubmed Central) - Jan 8, 2024
Achieving selectivity can be accomplished through three primary strategies, namely, binding to the induced lipophilic pocket, targeting the unique amino acid residue of PI3K?, or using atropisomerism to lock conformation. In this review, we focus on advances in the development of these ?-isoform-selective PI3K inhibitors, providing potential guidance for the further development of novel clinical candidates.
- | Journal: PI3K signaling promotes formation of lipid-laden foamy macrophages at the spinal cord injury site. (Pubmed Central) - Jan 8, 2024
RNA sequencing and in vitro analysis of foamy macrophages revealed increased autophagy and decreased phagocytosis after PI3K inhibition as potential mechanisms for reduced lipid accumulation. Together, our data suggest that the formation of pro-inflammatory foamy macrophages after SCI is due to the activation of PI3K signaling, which increases phagocytosis and decreases autophagy.
- | LY294002 / Eli Lilly
Journal: Angiotensin-(1-7) Improves Islet ?-cell Dedifferentiation by Activating PI3K/Akt/FoxO1 Pathway. (Pubmed Central) - Jan 8, 2024
Together, our data suggest that the formation of pro-inflammatory foamy macrophages after SCI is due to the activation of PI3K signaling, which increases phagocytosis and decreases autophagy. Ang-(1-7) may prevent high glucose-induced pathological dedifferentiation of pancreatic ?-cell by activating the PI3K/Akt/FoxO1 signaling pathway.
- | Piqray (alpelisib) / Novartis
Journal: Sodium-glucose cotransporter-2 inhibitors for hypergycemia in phosphoinositide 3-kinase pathway inhibition. (Pubmed Central) - Jan 8, 2024
Ang-(1-7) may prevent high glucose-induced pathological dedifferentiation of pancreatic ?-cell by activating the PI3K/Akt/FoxO1 signaling pathway. SGLT2 inhibitors are effective treatments for hyperglycemia in the setting of PI3K inhibition.
- | Journal: Spermidine activates adipose tissue thermogenesis through autophagy and fibroblast growth factor 21. (Pubmed Central) - Jan 7, 2024
Knockdown of Fgf21 or inhibition of PI3K/AKT and AMPK pathways in brown adipocytes abolished the thermogenesis-promoting effect of spermidine, suggesting that the effect of spermidine on adipose tissue thermogenesis might be regulated by FGF21 signaling via the PI3K/AKT and AMPK pathways. The present study provides new insight into the mechanism of spermidine on obesity and its metabolic complications, thereby laying a theoretical basis for the clinical application of spermidine.
- | LY294002 / Eli Lilly
Journal: TLQP-21 facilitates diabetic wound healing by inducing angiogenesis through alleviating high glucose-induced injuries on endothelial progenitor cells. (Pubmed Central) - Jan 7, 2024
The declined cell viability, increased apoptotic rate, reduced number of migrated cells, declined migration distance, repressed tube formation function, and inactivated PI3K/AKT/eNOS signaling observed in HG-treated EPCs were markedly reversed by TLQP-21, which were dramatically abolished by the co-culture of LY294002. Collectively, TLQP-21 facilitated diabetic wound healing by inducing angiogenesis through alleviating HG-induced injuries on EPCs.
- AZD3458 / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Synergistic Anticancer Effects of Combined Immunotherapy and PI3K? Inhibitors in Liver Cancer (New Hall) - Jan 6, 2024 - Abstract #APASL2024APASL_2043;
These findings suggest that inhibiting PI3K? could be a crucial part of the combined anti-tumor treatment using ICI and TKI in HCC.
- LY294002 / Eli Lilly
Chemoprotective Mechanisms of Skullcapflavone in Aflatoxin-induced toxICIty in Thle-3 Hepatocytes (Room 06, C-2) - Jan 6, 2024 - Abstract #APASL2024APASL_1536;
Remarkably, LYS294002, a specific inhibitor of PI3K, impaired SKI protective effect on THLE-3 suggesting the role of the pathway. This study is the first report describing the protective activities of SKI against AFB1-induced toxicity on human hepatocytes and may help contribute to the development of pharmaceutical leads targeting aflatoxin poisoning and carcinogenicity.
- sorafenib / Generic mfg.
Sorafenib combined with WAY-262611 inhibited Wnt/PI3K/Akt pathway in hepatocellular carcinoma () - Jan 6, 2024 - Abstract #APASL2024APASL_804;
in HCC. Therefore, DKK1 inhibitor may be a promising therapeutic strategy in HCC.
- | Journal: Lactiplantibacillus plantarum NKK20 Increases Intestinal Butyrate Production and Inhibits Type 2 Diabetic Kidney Injury through PI3K/Akt Pathway. (Pubmed Central) - Jan 6, 2024
By inhibiting PI3K pathway activation in HK-2 cells, butyrate maintains a tight junction structure of renal tubule epithelial cells and inhibits renal tissue fibrosis. These results suggest that NKK20 is helpful to prevent and treat the occurrence and aggravation of diabetic kidney injury.
- | LY294002 / Eli Lilly
Journal: 27-Hydroxycholesterol inhibits trophoblast fusion during placenta development by activating PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Jan 5, 2024
Moreover, the PI3K inhibitor LY294002 rescued the inhibitory effect of 27-OHC...This study was the first to prove that 27-OHC inhibits trophoblast cell fusion by Activating PI3K/AKT/mTOR signaling pathway. This study reveals a novel mechanism by which dyslipidemia during pregnancy results in adverse pregnancy outcomes.